Conditions: Diaphragmatic Dysfunction Muscle Weakness Muscle Fatigue
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 75
Healthy volunteers: no

Brief summary:
The effect of neuromuscular blocking agents (NMBA, e.g. rocuronium) on respiratory muscle activity is well known. However, since the availability of sugammadex, to our knowledge, no study has been conducted to evaluate the effect of this novel product on these muscles.

Our hypothesis is that by applying a different strategy in the use of neuromuscular blocking agents and their reversal agents we might see a different activity of the respiratory muscles.

Detailed description:

Arms:
arm 1: The patients will receive a single rocuronium dose, and no reversal agent. arm 2: The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent arm 3: The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent arm 4: The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent arm 5: The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent

Interventions: intervention 1: sugammadex 2mg/kg intervention 2: neostigmine intervention 3: sugammadex 4mg/kg intervention 4: placebo intervention 5: Single rocuronium dose intervention 6: Repeated rocuronium dose intervention 7: Continuous rocuronium infusion
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None intervention 5: None intervention 6: None intervention 7: None

Protocol document: